Skip to main content
Peptide Intel Hub laboratory research video
Peptide Intel Hub

Protocols · Metabolic

Vitamin B12 (cyanocobalamin / methylcobalamin): literature-reported ranges

B12 has decades of established clinical dosing literature for deficiency and pernicious anaemia. It is included here because it appears constantly as a blend component, where its role and its figures are usually left unstated.

Read this first

Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.

Compound at a glance

Class
Cobalamin vitamin
Reported half-life
Days to weeks, depending on hepatic stores
Routes used in the literature
Intramuscular, subcutaneous, oral and intranasal
Also written as

What the published studies reported

Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.

Deficiency correction — parenteral loading

Reported quantity
1000 µg intramuscularly
Frequency
Alternate days for 1–2 weeks
Study duration
Loading phase, then monthly to three-monthly

This is the standard published loading and maintenance structure.

High-dose oral studies

Reported quantity
1000–2000 µg orally
Frequency
Once daily
Study duration
4 weeks to 4 months

Passive diffusion at high oral quantities bypasses intrinsic-factor dependence.

Reconstitution maths

Supplied as a ready-made solution, typically 1000 µg/mL, so 1 mL draws 1000 µg. No reconstitution is needed.

Open the reconstitution calculator

How to read these figures

  • Cyanocobalamin, methylcobalamin and hydroxocobalamin differ in retention and are not equivalent milligram for milligram.
  • In blends, B12 often accounts for the colour of the solution and nothing else.
  • Correcting B12 without checking folate status is a documented pitfall in the clinical literature.

Sources and citations

These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.

  1. [1]
    Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: a systematic review of randomized controlled trials

    Butler CC, Vidal-Alaball J, Cannings-John R, et al. · Fam Pract · 2006 · PMID 16585128

    Systematic review of RCTs comparing intramuscular vitamin B12 injection regimens (e.g., 1000 mcg doses) against oral high-dose B12 for treating deficiency.

    View the record
  2. [2]
    Maintenance Treatment of Pernicious Anaemia by Massive Parenteral Doses of Vitamin B12 at Intervals of Twelve Weeks

    Kinloch JD, et al. · BMJ · 1960 · DOI 10.1136/bmj.1.5166.99

    Patients with pernicious anemia received large parenteral vitamin B12 doses at 12-week intervals to establish an effective maintenance dosing interval.

    View the record
  3. [3]
    Comparing the Efficacy and Tolerability of a New Daily Oral Vitamin B12 Formulation and Intermittent Intramuscular Vitamin B12 in Normalizing Low Cobalamin Levels: A Randomized, Open-Label, Parallel-Group Study

    Castelli MC, Friedman K, Sherry JH, et al. · Clin Ther · 2011 · PMID 21600388

    Patients with cobalamin deficiency were randomized to daily oral B12 versus intermittent intramuscular B12 injections (1000 mcg) to compare normalization of serum levels.

    View the record

Search the databases yourself

Read the Vitamin B12 (cyanocobalamin / methylcobalamin) research brief

Other metabolic compounds

All research protocols

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.

Share
© 2026 Peptide Intel Hub · Marbella · Educational research reference · For in-vitro research use only
Independent publication — we sell nothing. Supplier disclosure

Peptide Intel Hub is an independent educational publication. We are not affiliated with, owned by, or the same company as Regena Peptides and Regena.app (regena-peptides.com / regena.app). We do not sell, supply, ship or take payment for any compound. Because readers regularly ask where compounds discussed in published studies can be sourced for laboratory work, we list Regena Peptides and Regena.app as suppliers we have verified and trust — every batch is released with a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity). Outbound links are marked nofollow/sponsored and are provided to help readers, not to sell.